Revolution Medicines Reports Shareholder Vote Matters
Ticker: RVMDW · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Rev Med held a shareholder vote on June 20th regarding stock and warrants.
AI Summary
Revolution Medicines, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders on June 20, 2024. The filing details actions related to common stock and warrants.
Why It Matters
This filing indicates that Revolution Medicines held a shareholder vote, which is a routine but important event for corporate governance and potential future strategic decisions.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding a shareholder vote, not indicating any immediate financial distress or significant new risks.
Key Numbers
- 001-39219 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-2029180 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- June 24, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 700 Saginaw Drive (address) — Principal Executive Offices
- Redwood City, California (location) — Principal Executive Offices location
- 94063 (zip_code) — Principal Executive Offices zip code
FAQ
What specific matters were submitted to a vote of Revolution Medicines' security holders on June 20, 2024?
The filing indicates that matters related to common stock and warrants were submitted to a vote, but the specific details of these proposals are not elaborated in the provided text.
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report on the submission of matters to a vote of security holders, as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.
When was the earliest event reported in this filing?
The earliest event reported was on June 20, 2024.
Where are Revolution Medicines, Inc.'s principal executive offices located?
Revolution Medicines, Inc.'s principal executive offices are located at 700 Saginaw Drive, Redwood City, California, 94063.
What is Revolution Medicines, Inc.'s standard industrial classification?
Revolution Medicines, Inc.'s standard industrial classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-24 16:06:05
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq
Filing Documents
- d853953d8k.htm (8-K) — 35KB
- 0001193125-24-166939.txt ( ) — 187KB
- rvmdw-20240620.xsd (EX-101.SCH) — 4KB
- rvmdw-20240620_def.xml (EX-101.DEF) — 13KB
- rvmdw-20240620_lab.xml (EX-101.LAB) — 21KB
- rvmdw-20240620_pre.xml (EX-101.PRE) — 14KB
- d853953d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: June 24, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer